{"Content: ":"The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector[1] COVID-19 vaccine developed by the United States-based ImmunityBio.[2][1] The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa[3] ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.[4][5] In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[6] On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials.[7] The company \"hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020.\"[7] ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.[3][8][9][needs update]","Title":"ImmunityBio COVID-19 vaccine - Wikipedia","KeyID":"11188","URL":"https://en.wikipedia.org/wiki/ImmunityBio_COVID-19_vaccine"}